Lauren Riker insider trades: Pacira BioSciences (PCRX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Lauren reports to the SEC
Open-market buys and sales
39 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 8, 2026 | PCRX | ↓ Sell10b5-1 | 6,000 | $36.32 | $218K | Direct | Oct 9, 2026 (1d) |
| Jun 11, 2026 | PCRX | ↓ Sell10b5-1 | 6,115 | $23.50 | $144K | Direct | Jun 12, 2026 (1d) |
| Feb 2, 2026 | PCRX | ↓ Sell10b5-1 | 4,000 | $20.81 | $83K | Direct | Feb 3, 2026 (1d) |
| Jan 5, 2026 | PCRX | ↓ Sell10b5-1 | 1,416 | $24.24 | $34K | Direct | Jan 6, 2026 (1d) |
| Jun 4, 2025 | PCRX | ↓ Sell | 5,578 | $26.21 | $146K | Direct | Jun 5, 2025 (1d) |
| Jun 12, 2024 | PCRX | ↓ Sell | 3,970 | $28.72 | $114K | Direct | Jun 13, 2024 (1d) |
| Jul 5, 2023 | PCRX | ↓ Sell | 643 | $38.91 | $25K | Direct | Jul 7, 2023 (2d) |
| Jun 14, 2023 | PCRX | ↓ Sell | 6,366 | $38.42 | $245K | Direct | Jun 16, 2023 (2d) |
| Jun 7, 2023 | PCRX | ↓ Sell | 1,207 | $38.42 | $46K | Direct | Jun 7, 2023 (0d) |
| Jun 6, 2022 | PCRX | ↓ Sell | 1,150 | $61.37 | $71K | Direct | Jun 8, 2022 (2d) |
| Mar 10, 2022 | PCRX | ↓ Sell | 9,300 | $71.22 | $662K | Direct | Mar 14, 2022 (4d) |
| Jan 18, 2022 | PCRX | ↓ Sell | 2,500 | $64.97 | $162K | Direct | Jan 20, 2022 (2d) |
| Jul 29, 2021 | PCRX | ↓ Sell | 2,500 | $60.85 | $152K | Direct | Jul 30, 2021 (1d) |
| Jun 11, 2021 | PCRX | ↓ Sell | 2,003 | $59.85 | $120K | Direct | Jun 11, 2021 (0d) |
| Jun 4, 2021 | PCRX | ↓ Sell | 1,047 | $61.04 | $64K | Direct | Jun 8, 2021 (4d) |
| Mar 17, 2021 | PCRX | ↓ Sell | 3,520 | $71.42 | $251K | Direct | Mar 17, 2021 (0d) |
| Nov 13, 2020 | PCRX | ↓ Sell | 3,000 | $63.81 | $191K | Direct | Nov 17, 2020 (4d) |
| Sep 16, 2020 | PCRX | ↓ Sell | 3,000 | $60.34 | $181K | Direct | Sep 17, 2020 (1d) |
| Aug 11, 2020 | PCRX | ↓ Sell | 8,180 | $60.50 | $495K | Direct | Aug 13, 2020 (2d) |
| Jun 29, 2020 | PCRX | ↓ Sell | 6,000 | $49.47 | $297K | Direct | Jul 1, 2020 (2d) |
| Jun 5, 2020 | PCRX | ↓ Sell | 2,631 | $47.69 | $125K | Direct | Jun 8, 2020 (3d) |
| May 21, 2020 | PCRX | ↓ Sell | 4,000 | $44.03 | $176K | Direct | May 21, 2020 (0d) |
| Feb 10, 2020 | PCRX | ↓ Sell | 3,000 | $48.81 | $146K | Direct | Feb 12, 2020 (2d) |
| Feb 7, 2020 | PCRX | ↓ Sell | 1,000 | $46.81 | $47K | Direct | Feb 10, 2020 (3d) |
| Dec 23, 2019 | PCRX | ↓ Sell | 1,000 | $45.92 | $46K | Direct | Dec 26, 2019 (3d) |
| Nov 20, 2019 | PCRX | ↓ Sell | 1,176 | $44.14 | $52K | Direct | Nov 22, 2019 (2d) |
| Nov 11, 2019 | PCRX | ↓ Sell | 5,000 | $43.59 | $218K | Direct | Nov 12, 2019 (1d) |
| Jun 10, 2019 | PCRX | ↓ Sell | 2,126 | $44.28 | $94K | Direct | Jun 12, 2019 (2d) |
| Jun 4, 2019 | PCRX | ↓ Sell | 967 | $42.91 | $41K | Direct | Jun 6, 2019 (2d) |
| Nov 2, 2018 | PCRX | ↓ Sell | 1,000 | $54.35 | $54K | Direct | Nov 6, 2018 (4d) |
| Sep 24, 2018 | PCRX | ↓ Sell | 1,000 | $50.70 | $51K | Direct | Sep 26, 2018 (2d) |
| Aug 22, 2018 | PCRX | ↓ Sell | 1,667 | $44.48 | $74K | Direct | Aug 24, 2018 (2d) |
| Jun 4, 2018 | PCRX | ↓ Sell | 801 | $33.02 | $26K | Direct | Jun 6, 2018 (2d) |
| Dec 15, 2017 | PCRX | ↓ Sell | 340 | $43.70 | $15K | Direct | Dec 18, 2017 (3d) |
| Jun 7, 2017 | PCRX | ↓ Sell | 1,119 | $44.37 | $50K | Direct | Jun 9, 2017 (2d) |
| Jun 5, 2017 | PCRX | ↓ Sell | 601 | $43.32 | $26K | Direct | Jun 7, 2017 (2d) |
| Jun 7, 2016 | PCRX | ↓ Sell | 938 | $47.66 | $45K | Direct | Jun 8, 2016 (1d) |
| Mar 16, 2015 | PCRX | ↓ Sell | 5,000 | $95.34 | $477K | Direct | Mar 18, 2015 (2d) |
| Mar 14, 2013 | PCRX | ↓ Sell | 10,000 | $30.00 | $300K | Direct | Mar 18, 2013 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other PCRX insiders
Open-market trades in the last 12 months
About Lauren Riker's insider trades
Lauren Riker is Senior Vice President, Finance at Pacira BioSciences (PCRX). Since Mar 14, 2013, Lauren has reported no open-market purchases and 39 sales worth $5.8M on SEC Form 4. In the last 12 months: 4 sales ($479K).
4 sales (8% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include option exercises (19 filings), grants and awards (15 filings), shares withheld for taxes (6 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every PCRX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.